Dendritic Cell Vaccines:Current Status and Future Prospects in Immunotherapy

Niwarinda Arnold

Faculty of Pharmacy Kampala International University Uganda

Email: arnold.niwarinda@studwc.kiu.ac.ug

ABSTRACT

Dendritic cell (DC) vaccines represent a promising advancement in cancer immunotherapy, capitalizing on the unique ability of dendritic cells to initiate and regulate immune responses by presenting antigens to T-cells. These vaccines work by isolating dendritic cells from a patient, loading them with tumor-associated antigens (TAAs), and reinfusing them to stimulate an immune response against cancer cells. The FDA approval of sipuleucel-T (Provenge) for metastatic prostate cancer in 2010 marked a significant milestone in the field, demonstrating the potential for DC vaccines to prolong survival in cancer patients. This review explores the mechanism of action of dendritic cell vaccines, focusing on the process of antigen loading, dendritic cell maturation, and T-cell activation. It also discusses current clinical applications, challenges such as antigen selection, tumor immune evasion, and the high complexity of vaccine production. Future prospects for DC vaccines include personalized cancer vaccines, improved antigen delivery methods, and combination therapies with immune checkpoint inhibitors to enhance effectiveness. Dendritic cell vaccines offer a novel and potentially durable approach to cancer treatment, but further research is needed to optimize their efficacy and broaden their application across various cancer types and other diseases.

Keywords: Dendritic cell vaccines, Cancer immunotherapy, Tumor-associated antigens (TAAs), T-cell activation, Combination therapies

CITE AS: Niwarinda Arnold. (2024). Dendritic Cell Vaccines: Current Status and Future Prospects in Immunotherapy. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(2):7-12. https://doi.org/10.59298/RIJBAS/2024/42712